Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 886 to 900 of 1553 results for do not do recommendations

  1. How effective and cost effective are universal, education-based alcohol interventions for children and young people aged 11 to 25 with SEND?

    Recommendation ID NG135/3 Question How effective and cost effective are universal, education-based alcohol interventions for children and

    Research recommendation
    Published
    25 October 2019

  2. What components of alcohol education delivery contribute to its effectiveness for children and young people aged 11 to 18 in full-time education, and those with special educational needs and disabilities (SEND) up to the age of 25?

    Recommendation ID NG135/1 Question What components of alcohol education delivery contribute to its effectiveness for children and young

    Research recommendation
    Published
    25 October 2019

  3. Truncal treatment with or without concurrent tributary treatment:- What is the clinical and cost effectiveness of concurrent phlebectomies or foam sclerotherapy for varicose tributaries during truncal endothermal ablation for varicose veins compared with: - truncal endothermal ablation without concurrent phlebectomies or foam sclerotherapy? - truncal endothermal ablation with phlebectomies or foam sclerotherapy, if needed, 6–12 weeks later?

    Recommendation ID CG168/4 Question Truncal treatment with or without concurrent tributary treatment:- What is the clinical and cost...

    Research recommendation
    Published
    9 June 2015

  4. Patient and public involvement policy

    Read NICE's patient and public involvement policy.

  5. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (TA862)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.

    Technology appraisal guidance
    Published
    1 February 2023
    View recommendations

    Sections for TA862

  6. What are the long-term outcomes, both psychotic and nonpsychotic, for children and young people with attenuated or transient psychotic symptoms suggestive of a developing psychosis, and can the criteria for 'at risk states' be refined to better predict those who will and those who will not go on to develop psychosis?

    Recommendation ID CG155/1 Question What are the long-term outcomes, both psychotic and nonpsychotic, for children and young people with

    Research recommendation
    Published
    9 June 2015

  7. Evidence on the safety and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    Recommendation ID IPG737/01 Question Evidence on the safety and efficacy of prostatic urethral temporary implant insertion for lower...

    Research recommendation
    Published
    30 September 2022

  8. Evidence on the efficacy and safety of neurostimulation of lumbar muscles for refractory non-specific chronic low back pain is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    Recommendation ID IPG739/01 Question Evidence on the efficacy and safety of neurostimulation of lumbar muscles for refractory...

    Research recommendation
    Published
    30 September 2022

  9. Effectiveness and cost effectiveness of drug misuse prevention interventions for groups vulnerable to drug misuse:- What is the effectiveness and cost effectiveness of drug misuse prevention interventions for groups vulnerable to drug misuse in the UK?

    Recommendation ID NG64/3 Question Effectiveness and cost effectiveness of drug misuse prevention interventions for groups vulnerable to

    Research recommendation
    Published
    4 May 2017

  10. Recognising dying:- What can multiprofessional teams do to reduce the impact of uncertainty of recognising when a person is entering the last days of life on clinical care, shared decision-making and communication with the dying person and those important to them?

    Recommendation ID NG31/1 Question Recognising dying:- What can multiprofessional teams do to reduce the impact of...

    Research recommendation
    Published
    27 January 2016

  11. What is the effectiveness, cost effectiveness and acceptability of the whole family approach to carers' assessments?

    Recommendation ID NG150/1 Question What is the effectiveness, cost effectiveness and acceptability of the whole family approach to...

    Research recommendation
    Published
    10 February 2020

  12. MRI fusion biopsy systems for diagnosing prostate cancer (HTG678)

    Evidence-based recommendations on MRI fusion biopsy systems for diagnosing prostate cancer.

    HealthTech guidance
    Published
    24 May 2023
    View recommendations

    Sections for HTG678

  13. Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (HTG438)

    Evidence-based recommendations on virtual chromoendoscopy (VCE) using NBI, FICE or i-scan to assess colorectal polyps of 5 mm or less during colonoscopy.

    HealthTech guidance
    Published
    10 May 2017

    Sections for HTG438

  14. Siponimod for treating secondary progressive multiple sclerosis (TA656)

    Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    18 November 2020
    View recommendations

    Sections for TA656

  15. Recommendation 1 Research studies and trials. Who should take action? Research councils, commissioners and funders.

    Recommendation ID PH47/1 Question Recommendation 1 Research studies and trials. Who should take action? Research councils,...

    Research recommendation
    Published
    9 June 2015